References
- Treon S P, Gertz M A, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan A R, et al. Update on treatment recommendations from the third international workshop on Waldenstrom's macroglobulinemia. Blood 2006; 107: 3442–3446
- Morel P, Duhamel A, Gobbi P, Dimopoulos M, Dhodapkar M, McCoy J, et al. International Prognostic Scoring System (IPSS) for Waldenström's Macroglobulinemia (WM). Blood 2006; 108: 42a
- Dhodapkar M V, Jacobson J L, Gertz M A, Rivkin S E, Roodman G D, Tuscano J M, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98: 41–48
- Mead G P, Carr-Smith H D, Drayson M T, Morgan G J, Child J A, Bradwell A R. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348–354
- Mayo M M, Johns G S. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol 2007; 153: 44–65
- Durie B G, Harousseau J L, Miguel J S, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 2220
- Rajkumar S V, Kyle R A, Therneau T M, Clark R J, Bradwell A R, Melton L J, III, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004; 127: 308–310
- Gertz M A, Lacy M Q, Dispenzieri A, Hayman S R. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma 2005; 6: 208–219
- Owen R G, Treon S P, Al-Katib A, Fonseca R, Greipp P R, McMaster M L, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110–115
- Katzmann J A, Abraham R S, Dispenzieri A, Lust J A, Kyle R A. Diagnostic performance of quantitative κ and λ free light chain assays in clinical practice. Clin Chem 2005; 51: 878–881
- Dispenzieri A, Lacy M Q, Katzmann J A, Rajkumar S V, Abraham R S, Hayman S R, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378–3383
- Drayson M, Tang L X, Drew R, Mead G P, Carr-Smith H, Bradwell A R. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900–2902
- Nowrousian M R, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11: 8706–8714
- Dimopoulos M A, Kyle R A, Anagnostopoulos A, Treon S P. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23: 1564–1577
- Ghobrial I M, Fonseca R, Gertz M A, Plevak M F, Larson D R, Therneau T M, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133: 158–164